<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247594</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-029</org_study_id>
    <nct_id>NCT04247594</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD</brief_title>
  <official_title>A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose escalation study to evaluate the safety and tolerability of voxelotor at daily
      doses of 1500 mg to 3000 mg in participants with sickle cell disease (SCD). The study is
      designed to include 2 separate cohorts. In Cohort A participants will undergo up to 4 periods
      of voxelotor administration at progressively higher dose levels from 1500 mg until either a
      maximum tolerated dose (MTD) or 3000 mg orally daily is reached. Cohort B (following Cohort
      A) will assess the tolerability and safety of doses higher than 1500 mg administered without
      up-titration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent AEs</measure>
    <time_frame>approximately 200 days</time_frame>
    <description>Treatment emergent AEs including SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb and clinical measures of hemolysis (unconjugated bilirubin, % reticulocyte, absolute reticulocyte, and lactate dehydrogenase [LDH]) from Baseline</measure>
    <time_frame>approximately 200 days</time_frame>
    <description>Change in Hb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an Hb increase &gt; 1 g/dL compared to Baseline</measure>
    <time_frame>approximately 200 days</time_frame>
    <description>participants with an Hb increase &gt; 1 g/dL compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive progressively higher doses of voxelotor administration starting from 1500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive doses higher than 1500 mg administered without up-titration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voxelotor</intervention_name>
    <description>synthetic small molecule supplied as 500 mg tablets</description>
    <arm_group_label>Cohort A open label</arm_group_label>
    <arm_group_label>Cohort B open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female with sickle cell disease

          -  Documentation of SCD genotype HbSS or HbSB0

          -  Age 18 to &lt; 60 years, inclusive

          -  Participants, who if female and of child bearing potential, agree to use highly
             effective methods of contraception or practicing abstinence from study start to 30
             days after the last dose of study drug, and who if male, agree to use barrier methods
             of contraception or practice abstinence from study start to 30 days after the last
             dose of study drug

          -  Participant has provided documented informed consent

        Exclusion Criteria:

          -  More than 10 vaso-occlusive crises (VOCs) within 12 months of screening that required
             a hospital, emergency room, or clinic visit

          -  Female participant who is breast feeding or pregnant

          -  Hospitalized for sickle cell crisis or other vaso-occlusive event prior to 30 days of
             dosing (ie, a vaso-occlusive event cannot be within 30 days prior to dosing)

          -  Participants with known active hepatitis A, B, or C or who are known to be human
             immunodeficiency virus (HIV) positive

          -  Severe renal dysfunction or on chronic dialysis

          -  History of malignancy within the past 2 years prior to treatment Day 1 requiring
             chemotherapy and/or radiation (with the exception of local therapy for non-melanoma
             skin malignancy)

          -  History of unstable or deteriorating cardiac or pulmonary disease within 6 months
             prior to consent including but not limited to the following:

          -  Participated in another clinical trial of an investigational agent or medical device
             within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is
             currently participating in another trial of an investigational agent or medical device

          -  Inadequate venous access as determined by the Investigator/site staff

          -  Ongoing or recent (within 2 years) substance abuse

          -  Inability to undergo magnetic resonance imaging (MRI) or cardiopulmonary exercise test
             (CPET) assessments (Cohort B only)

          -  Known allergy to voxelotor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Will Tappe, MD</last_name>
    <phone>(650) 825-4678</phone>
    <email>wtappe@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theresa Thuener</last_name>
    <phone>+1 650 741 7710</phone>
    <email>tthuener@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yemi Adelaja</last_name>
      <phone>+44 (0)779 907 6144</phone>
      <email>yemi.adelaja@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Henry Fok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thompson Olaoni</last_name>
      <phone>+44 (0)207 188 7188</phone>
      <phone_ext>56496</phone_ext>
      <email>thompson.olaoni@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jo Howard, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zainab Alashe</last_name>
      <phone>+44 (0)203 313 8553</phone>
      <email>zainab.alashe@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Mark Layton, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Homerton University</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Vize</last_name>
      <phone>+44 (0)208 510 5785</phone>
      <email>jessica.vize@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Dimitris Tsitsikas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Torre</last_name>
      <phone>+44 (0) 20 3299 5501</phone>
      <email>karen.torre@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Jen Lewis</last_name>
      <email>jen.lewis2@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Moji Awogbade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital, Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasnima Ferdousi</last_name>
      <phone>+44 (0)203 246 0261</phone>
      <email>tasnima.ferdousi@nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Telfer, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease, SCD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

